Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease

Active Psoriatic Arthritis Clinical Trial

Official title: A Multicenter, Open-Label Study to Evaluate the Safe and Effective Use of an Electro-Mechanical Injection Device (E-Device) for the Subcutaneous Self-Injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease

Status Completed

Clinical Trial Summary

The purpose of the study is to evaluate the ability of subjects who are already prescribed Certolizumab Pergol therapy and have been self injecting with prefilled syringes for at least the previous three months, to safely and effectively self-inject Certolizumab Pegol (CZP) using the e-Device and to evaluate the post-use structural integrity of used devices and cassettes via visual examination.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Active Ankylosing Spondylitis
• Active Psoriatic Arthritis
• Arthritis
• Arthritis, Psoriatic
• Arthritis, Rheumatoid
• Crohn Disease
• Moderate and Severe Active Rheumatoid Arthritis
• Moderately to Severely Active Crohn's Disease
• Spondylitis
• Spondylitis, Ankylosing

• NCT number: NCT03357471
• Study type: Interventional
• Source: UCB Pharma
• Status: Completed
• Phase: Phase 3
• Start date: November 3, 2017
• Completion date: July 2, 2018